IPCALABIPCA Laboratories Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
The picture
- • Profit growth: 341.6% YoY
- • ROCE: 17.6%
- • Debt/Equity: 0.08
- • RSI: 53
- • MACD: fresh bullish crossover
- • Price vs EMA21: above
- • Pullback to 21-EMA signal (setup quality 61%)
Bull case
- • Profit growth: 341.6% YoY
- • ROCE: 17.6%
- • Debt/Equity: 0.08
- • RSI: 53
Bear case
- • Revenue growth: 6.3% YoY
- • Dividend yield: 0.10%
- • Price vs SMA50: below
- • Supertrend: bearish
Key risks
- • Revenue growth: 6.3% YoY
- • Dividend yield: 0.10%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹67.33). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.